Important: Regorafenib 40 mg is a prescription anticancer medicine that should only be used under the supervision of an experienced oncology specialist.
Regorafenib carries a boxed warning for severe and potentially fatal liver toxicity in U.S. prescribing information. Liver function must be monitored before and during treatment.
What Is Regorafenib 40 mg?
Regorafenib 40 mg Tablets contain regorafenib, an oral multikinase inhibitor used in the treatment of certain advanced cancers.
Regorafenib is a targeted anticancer medicine that inhibits several protein kinases involved in tumor growth, blood vessel formation and cancer-related signaling pathways.
Cancer cells depend on complex signaling networks to grow, survive and spread.
Some tumors also stimulate the development of new blood vessels, a process known as angiogenesis.
These blood vessels supply oxygen and nutrients that support tumor development.
Regorafenib interferes with multiple signaling pathways involved in these processes.
Its kinase targets include VEGFR1, VEGFR2, VEGFR3, TIE2, KIT, RET, RAF-1, BRAF, PDGFR and FGFR, among others.
By inhibiting these pathways, regorafenib can slow cancer progression in selected patients.
Regorafenib is used for certain patients with previously treated metastatic colorectal cancer, advanced gastrointestinal stromal tumors and hepatocellular carcinoma.
Eligibility depends on the cancer type, prior treatments, clinical condition and applicable prescribing guidelines.
Regorafenib is not conventional cytotoxic chemotherapy. It is classified as a targeted multikinase inhibitor.
However, it can cause significant adverse effects and requires close medical monitoring.
Important: Regorafenib is not a guaranteed cure for cancer. Its purpose in approved advanced cancer settings is to provide clinical benefit, which may include delaying disease progression.
How Does Regorafenib 40 mg Work?
1. Inhibits Multiple Protein Kinases
Regorafenib blocks several enzymes involved in tumor signaling.
2. Targets VEGF Receptor Signaling
It inhibits VEGFR1, VEGFR2 and VEGFR3, which participate in blood vessel development.
3. Reduces Tumor Angiogenesis
By interfering with angiogenic signaling, regorafenib can limit the formation of blood vessels that support tumor growth.
4. Inhibits Tumor Growth Signaling
Regorafenib targets kinases involved in cancer cell proliferation and survival.
5. Targets KIT Signaling
KIT inhibition is relevant to certain gastrointestinal stromal tumors.
6. Inhibits RAF-Related Pathways
Regorafenib inhibits RAF-family kinases involved in intracellular signaling.
7. Affects the Tumor Microenvironment
It targets signaling pathways involved in the surrounding environment that supports tumor development.
8. Helps Delay Disease Progression
Through its combined effects, regorafenib may slow tumor progression in selected patients.
Important: Treatment response varies depending on cancer type, previous therapies, tumor biology and individual patient factors.
Uses of Regorafenib 40 mg
1. Metastatic Colorectal Cancer
Regorafenib is approved in certain jurisdictions for adults with metastatic colorectal cancer who have previously received specified standard treatments.
These generally include fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, anti-VEGF therapy and anti-EGFR therapy when appropriate.
Treatment eligibility depends on the applicable product label and clinical guidelines.
2. Gastrointestinal Stromal Tumors (GIST)
Regorafenib is used for certain patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumors who have previously received imatinib and sunitinib.
3. Hepatocellular Carcinoma (HCC)
Regorafenib is used for selected patients with hepatocellular carcinoma who have previously been treated with sorafenib.
Patients require careful assessment of liver function and overall clinical condition.
4. Previously Treated Advanced Cancer
Regorafenib may be considered when the patient’s cancer matches an approved indication and previous treatment requirements.
5. Tumor Progression Control
The medicine may help delay disease progression in selected patients.
6. Anti-Angiogenic Cancer Treatment
Regorafenib inhibits signaling involved in tumor blood vessel formation.
7. Targeted Oncology Therapy
Regorafenib may form part of an individualized oncology treatment plan.
Important: Regorafenib should not be promoted as an approved treatment for all cancers. Investigational or off-label uses require separate clinical justification and should not be presented as established indications.
How to Take Regorafenib 40 mg Tablets
Regorafenib must be taken exactly as prescribed by an oncology specialist.
General Administration Instructions
- Take the prescribed number of tablets at the same time each day.
- Swallow the tablets whole with water.
- Do not crush, split or chew the tablets.
- Take the medicine after a low-fat meal according to the product instructions.
- Follow the prescribed treatment cycle.
- Do not increase or decrease the dose independently.
- Attend scheduled blood tests and oncology appointments.
- Report severe side effects promptly.
- Avoid grapefruit and grapefruit juice unless your oncology team specifically advises otherwise.
- Store the medicine in its original container according to the product label.
Standard Dosage Information
| Dosage Detail | General Guidance |
|---|---|
| Tablet Strength | 40 mg |
| Usual Starting Dose | 160 mg Once Daily |
| Tablets per Standard Starting Dose | Four 40 mg Tablets |
| Treatment Days | Days 1–21 |
| Cycle Length | 28 Days |
| Treatment Break | Days 22–28 |
| Administration | After a Low-Fat Meal |
| Dose Adjustments | May Be Reduced to 120 mg or 80 mg Daily |
| Minimum Recommended Dose | 80 mg Daily Under Standard Label-Based Dose Modifications |
| Treatment Duration | Until Progression or Unacceptable Toxicity, as Directed |
Important: This is a commonly labeled adult regimen for approved indications, not an individualized prescription. Oncology specialists may modify the starting dose or schedule according to clinical circumstances and applicable protocols.
What Is Considered a Low-Fat Meal?
The U.S. prescribing information describes a low-fat meal as containing less than 600 calories and less than 30% of calories from fat.
Follow the instructions supplied with the specific product.
Can Regorafenib Be Taken on an Empty Stomach?
The standard labeled administration instructions recommend taking it after a low-fat meal.
What If a Dose Is Missed?
Take the missed dose on the same day when remembered, according to the product instructions.
Do not take two doses on the same day to compensate for a missed dose.
What If Vomiting Occurs After a Dose?
Do not take an additional dose after vomiting unless specifically instructed by the oncology team.
What If Too Much Regorafenib Is Taken?
Contact the treating oncology team or seek urgent medical assistance.
Excessive dosing may increase the risk of serious toxicity.
How Long Does Regorafenib 40 mg Take to Work?
Regorafenib begins affecting its molecular targets after administration, but clinical response cannot be assessed immediately.
During the First Treatment Cycle
The medicine begins inhibiting relevant kinase pathways.
Over Subsequent Treatment Cycles
The oncology team evaluates tolerability and treatment response.
During Scheduled Imaging
CT scans, MRI scans or other appropriate assessments may be used to evaluate disease progression.
During Continued Treatment
Treatment may continue while clinical benefit is maintained and adverse effects remain manageable.
Important: The absence of immediate symptom improvement does not necessarily indicate treatment failure. Response must be assessed by the oncology specialist.
Common Side Effects
Commonly reported adverse effects include:
- Hand-Foot Skin Reaction
- Fatigue
- Weakness
- Diarrhea
- Reduced Appetite
- Weight Loss
- High Blood Pressure
- Mouth Inflammation
- Mouth Ulcers
- Voice Changes
- Hoarseness
- Nausea
- Abdominal Discomfort
- Skin Rash
- Elevated Liver Enzymes
- Infections
- Pain
Side effects may require supportive treatment, temporary interruption or dose reduction.
Serious Side Effects
Regorafenib may cause serious or life-threatening adverse reactions.
Seek urgent medical care for:
- Yellowing of the skin or eyes
- Dark urine
- Severe abdominal pain
- Vomiting blood
- Black or bloody stools
- Severe or uncontrolled bleeding
- Severe headache with confusion or visual changes
- Chest pain
- Sudden shortness of breath
- Severe skin reactions
- Signs of serious infection
- Severe dehydration
- Sudden neurological symptoms
- Significant wound-healing problems
Important Serious Risks
1. Severe Hepatotoxicity
Regorafenib can cause severe liver injury, including liver failure and death.
Liver function tests are required before treatment and regularly during therapy.
2. Hemorrhage
Serious and sometimes fatal bleeding may occur.
3. Hypertension
Regorafenib can cause significant increases in blood pressure.
4. Hand-Foot Skin Reaction
Painful redness, swelling, blistering or thickened skin may develop on the palms and soles.
5. Gastrointestinal Perforation or Fistula
Rare but serious gastrointestinal complications may occur.
6. Myocardial Ischemia and Infarction
Regorafenib may increase the risk of serious cardiac ischemic events.
7. Reversible Posterior Leukoencephalopathy Syndrome (RPLS/PRES)
A rare neurological condition may cause headache, seizures, confusion or visual disturbances.
8. Impaired Wound Healing
Regorafenib may interfere with wound healing.
9. Severe Infections
Serious infections may occur during treatment.
10. Embryo-Fetal Toxicity
Regorafenib can harm a developing fetus.
Contraindications & Precautions
1. Liver Toxicity
Severe liver injury is a major safety concern.
Liver function should be assessed before treatment and monitored regularly.
2. Liver Function Monitoring
U.S. labeling recommends liver function tests before treatment, at least every two weeks during the first two months, and at least monthly thereafter or as clinically indicated.
3. Hypertension
Blood pressure should be controlled before treatment and monitored during therapy.
4. Bleeding Disorders
Patients with a history of significant bleeding require careful evaluation.
5. Anticoagulant Therapy
Patients receiving anticoagulants, including warfarin, may require additional monitoring.
6. Heart Disease
Patients with ischemic heart disease or other significant cardiovascular conditions require careful assessment.
7. Gastrointestinal Perforation
Severe abdominal pain or signs of gastrointestinal perforation require urgent evaluation.
8. Hand-Foot Skin Reaction
Patients should report painful skin changes early.
































































